<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842982</url>
  </required_header>
  <id_info>
    <org_study_id>CHIPPI-1808</org_study_id>
    <secondary_id>2018-003680-62</secondary_id>
    <nct_id>NCT03842982</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)</brief_title>
  <acronym>CHIPPI</acronym>
  <official_title>Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multicenter, interventional and randomized study which evaluates the use&#xD;
      of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking&#xD;
      Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This&#xD;
      study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC&#xD;
      combined with standard care (PDS or IDS) or standard care alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the efficacy, in terms of disease-free&#xD;
      survival (DFS), the use of HIPEC treatment combined with standard care (PDS or IDS) or&#xD;
      standard care alone (PDS or IDS alone).&#xD;
&#xD;
      Secondary objectives of the study include:&#xD;
&#xD;
        -  Evaluating the efficacy of HIPEC in terms of overall survival (OS) in combination with&#xD;
           standard of care&#xD;
&#xD;
        -  Evaluating the morbidity associated with HIPEC.&#xD;
&#xD;
        -  Evaluating the trade-off between efficacy and morbidity using the Q-TWiST approach.&#xD;
&#xD;
        -  Evaluating the impact of HIPEC in terms of quality of life.&#xD;
&#xD;
      Exploratory objectives (optional) include:&#xD;
&#xD;
        -  Evaluating the impact of HIPEC on the count of residual viable cells (evaluated by flow&#xD;
           cytometry) in abdominal drainage fluids for patients recruited in Centre Oscar Lambret&#xD;
           only.&#xD;
&#xD;
        -  Constituting a biobank (tumoral samples and blood samples) for future translational&#xD;
           researches&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>From randomization to first progression, relapse or death from any cause, whichever came first, assessed up to 5 years. (Follow-up up to 5 years)</time_frame>
    <description>The DFS will be measured to assess the efficacy of the combination treatment of surgery and HIPEC or standard care alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to first progression, relapse or death from any cause , whichever came first, assessed up to 5 years..</time_frame>
    <description>The overall survival will be measured to assess the efficacy of HIPEC in combination with standard care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>Covers the whole treatment duration from Randomization up to the end of treatment (surgery or CT) plus 30 days.</time_frame>
    <description>The adverse events (AE) are collected to evaluate the impact of HIPEC on the safety and on the feasibility of adjuvant treatment (if any) is planned after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Q-TWiST</measure>
    <time_frame>Over the 5 year surveillance period</time_frame>
    <description>Q-Twist (Quality-adjusted time without symptoms of disease or toxicity) will be calculated from the survival tile (OS and DFS) and AE (adverse events) data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patient (QLQC30)</measure>
    <time_frame>Up to 2 years after the end of treatment (every 3 month)</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Score 30 (QLQ-C30) will be used to measure the quality of life of the patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patient (QLQOV28)</measure>
    <time_frame>Up to 2 years after the end of treatment (every 3 month)</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28) will be used to measure the quality of life of the patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">362</enrollment>
  <condition>Ovary Neoplasms</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (PDS or IDS + HIPEC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy)&#xD;
Patients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).&#xD;
Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (PDS or IDS)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy ONLY (standard care, without HIPEC)&#xD;
Patients in the control group will ONLY receive the standard care, which consists of surgery (PDS or IDS) with Neo and/or Adjuvant chemotherapy (CT). Patients undergoing PDS will be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).&#xD;
Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.&#xD;
Administration of the dose should be according the following schedule:&#xD;
50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.&#xD;
The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.</description>
    <arm_group_label>Arm A (PDS or IDS + HIPEC)</arm_group_label>
    <other_name>Hyperthermic intraperitoneal chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pre-eligibility criteria to be checked before surgery for pre-registration&#xD;
&#xD;
          1. Age ≥18 years and ≤ 76 years&#xD;
&#xD;
          2. Histologically proven primary epithelial ovarian carcinoma or fallopian tube carcinoma&#xD;
             or peritoneal carcinoma (including serous papillary adenocarcinoma, clear-cell&#xD;
             carcinoma, mucinous adenocarcinoma and endometrioid carcinoma)&#xD;
&#xD;
          3. Pre-therapeutic FIGO (International Federation of Gynecology and Obstetrics) stage III&#xD;
&#xD;
          4. Patient eligible for&#xD;
&#xD;
               1. Primary Debulking Surgery (PDS) with planned adjuvant chemotherapy +/-&#xD;
                  bevacizumab or other targeted therapy&#xD;
&#xD;
               2. Or Interval Debulking Surgery (IDS) after neo-adjuvant chemotherapy +/-&#xD;
                  bevacizumab or other targeted therapy, with or without planned adjuvant&#xD;
                  chemotherapy +/- bevacizumab or other targeted therapy. In case of neo-adjuvant&#xD;
                  chemotherapy, surgery should be performed in a time interval of 3 to 5 weeks in&#xD;
                  case of chemotherapy without bevacizumab, and in a time interval of 4 to 6 weeks&#xD;
                  if chemotherapy is combined with bevacizumab. The patient remains eligible for&#xD;
                  the study if surgery is delayed beyond the recommended time interval.&#xD;
&#xD;
          5. WHO (World Health Organization Performance Status) ≤ 2&#xD;
&#xD;
          6. Physical status score ASA (American Society of Anesthesiologists) ≤ 2&#xD;
&#xD;
          7. Adequate bone marrow and renal function, as evidenced by the following tests performed&#xD;
             within 7 days prior to surgery:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥1,500/mm3&#xD;
&#xD;
               -  Platelets ≥100,000/mm3&#xD;
&#xD;
               -  Aspartate aminotransferase (ALT)/ Alanine aminotransferase (ALT) ≤2.5 × upper&#xD;
                  limit of normal (ULN) (≤5.0 × ULN in case of liver metastases)&#xD;
&#xD;
               -  Total bilirubin ≤1.5 × ULN (except in case of Gilbert's disease)&#xD;
&#xD;
               -  Creatinine clearance ≥ 60 mL/ min&#xD;
&#xD;
          8. Negative serum pregnancy test within 7 days prior to surgery for women of childbearing&#xD;
             potential. For non-menopausal women, if no hysterectomy is planned, willing to accept&#xD;
             the use of an effective contraceptive regimen during the treatment period and at least&#xD;
             6 months after the end of treatment (surgery or adjuvant chemotherapy)&#xD;
&#xD;
          9. Absence of contraindication to receive the products used in this study (cisplatin and&#xD;
             products used in neo-adjuvant/ adjuvant chemotherapy) according to the most recent&#xD;
             SmPC (Summary of Product Characteristics) of these products&#xD;
&#xD;
         10. Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including&#xD;
             follow-up&#xD;
&#xD;
         11. Signed written informed consent&#xD;
&#xD;
         12. Patient covered by the French or Belgian &quot;Social Security&quot; regime Criteria to be&#xD;
             checked per-operatively for confirmation of enrolment and randomization&#xD;
&#xD;
         13. Residual disease after surgery (cytoreduction score CC) CC-0 (no macroscopic residue)&#xD;
             or CC-1 (residue &lt; 2.5 mm)&#xD;
&#xD;
         14. Per-operative hemorrhage &lt; 2.5 L&#xD;
&#xD;
         15. Strictly less than 3 digestive resections performed during surgery&#xD;
&#xD;
         16. Diuresis maintained during surgery, without oliguria or anuria (per-operatory diuresis&#xD;
             ≥ 0,5 mL/ kg/ h)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Benign disease, borderline disease, non epithelial ovarian carcinoma or carcinosarcoma&#xD;
&#xD;
          2. Cirrhosis&#xD;
&#xD;
          3. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in&#xD;
             the formulation&#xD;
&#xD;
          4. Auditory impairment&#xD;
&#xD;
          5. Dehydration or intercurrent disease that contraindicates hyperhydration (including&#xD;
             cardio-respiratory disease)&#xD;
&#xD;
          6. Other uncontrolled intercurrent disease including, but not limited to: diabetes;&#xD;
             hypertension; symptomatic congestive heart or pulmonary failure; renal, hepatic or&#xD;
             severe gastrointestinal (associated with diarrhea) chronic disease&#xD;
&#xD;
          7. Any unresolved NCI-CTCAE Grade ≥ 2 toxicity from previous anticancer therapy&#xD;
             (excluding alopecia)&#xD;
&#xD;
          8. Concomitant treatment with prophylactic phenytoin&#xD;
&#xD;
          9. Receipt of live attenuated vaccine, including yellow fever vaccine, within 30 days&#xD;
             prior to inclusion (and, if patient is enrolled, up to 30 days after the last&#xD;
             administration of study treatment)&#xD;
&#xD;
         10. Pregnant or breastfeeding woman&#xD;
&#xD;
         11. Psychiatric illness or social situation that would limit compliance with study&#xD;
             requirement, substantially increase the risk of side effects, or compromise the&#xD;
             ability of the patient to give written informed consent&#xD;
&#xD;
         12. Inability to comply with medical follow-up of the trial (geographical, social or&#xD;
             psychic reasons)&#xD;
&#xD;
         13. Person under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women with ovarian cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice NARDUCCI, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret, Lille, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie VANSEYMORTIER</last_name>
    <phone>+33 3 20 29 59 18</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabrice MULOT</last_name>
    <phone>+33 3 20 29 59 18</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romuald WERNERT, MD</last_name>
      <email>romuald.wernert@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Romuald WERNERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro RARO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeria DE FRANCO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Augustin REYNARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick SOULIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paule AUGEREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne PATSOURIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elouen BOUGHALEM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric BIGOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margot NOBLECOURT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor SIMMET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion DE VRIES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine MARTIN-FRANCOISE, MD</last_name>
      <email>marsa@baclessse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine MARTIN-FRANCOISE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean François LE BRUN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence JOLY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emeline MERIAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe POMEL, MD</last_name>
      <email>christophe.pomel@clermont.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe POMEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline CORNOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie DUBOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morgane MASSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Ange MOURET-REYNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice NARDUCCI, MD</last_name>
      <email>f-narducci@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice NARDUCCI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine HUDRY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric LEBLANC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril ABDEDDAIM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick CHEVALIER-PLACE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfred BASSIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte BELLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie CHEVALIER-EVAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie KACZMAREK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samira MAKHLOUFI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre COLLINET, MD, PhD</last_name>
      <email>pierre.collinet@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre COLLINET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clarisse EVENO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme PHALIPPOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe DESAUW, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne PLOQUIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LAMBAUDIE, MD, PhD</last_name>
      <email>lambaudiee@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Eric LAMBAUDIE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles HOUVENAEGHEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume BLACHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura SABIANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien BARROU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Antonietta CAPPIELLO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali PROVANSAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédérique ROUSSEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud SABATIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM-Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Emmanuel COLOMBO, MD</last_name>
      <email>Pierre-Emmanuel.Colombo@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Emmanuel COLOMBO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien CARRERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne MOURREGOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François QUENET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe ROUANET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia SGARBURA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique D'HONDT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel FABBRO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Sophie BATS, MD</last_name>
      <email>anne-sophie.bats@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Sophie BATS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas DELANOY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri AZAIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrica BENTIVEGNA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meriem KOUAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huyên-Thu NGUYEN-XUAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoual BAKRIN, MD</last_name>
      <email>naoual.bakrin@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Witold GERTYCH, MD</last_name>
      <email>witold.gertych@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Naoual BAKRIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Witold GERTYCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier GLEHEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vahan KEPENEKIAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit YOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre DESCARGUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Adrien BOLZE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Mathilde</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoît RESCH, MD</last_name>
      <email>benoit.resch@clinique-mathilde.fr</email>
    </contact>
    <investigator>
      <last_name>Benoït RESCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc BARON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien COGET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clotilde HENNETIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morgane PERRIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Jacques TUECH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre MARQUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine MEZZANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile HENNEBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agathe CROUZET, MD</last_name>
      <email>agathe.crouzet@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Agathe CROUZET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien CARRILHO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel DE GOURNAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albane POTEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laetitia AUGUSTO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie GOUERANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile GUILLEMET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianne LEHEURTEUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille PETRAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chérif AKLADIOS, MD</last_name>
      <email>Cherif.AKlADlOS@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas BOISRAME, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chérif AKLADIOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauriane EBERST, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric MARCHAL, MD</last_name>
      <email>f.marchal@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric MARCHAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda FERNANDEZ DIEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline GAVOILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Christine KAMINSKY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécilia CERIBELLI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien GOUY, MD</last_name>
      <email>sebastien.gouy@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Sébastien GOUY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra LEARY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Primary Debulking Surgery</keyword>
  <keyword>Interval Debulking Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

